Cabozantinib

Generic Name: Cabozantinib

Brand Names: Cabometyx, Cometriq

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₂₄FN_₃O_₅

CAS Number: 849217-68-1

Unique Ingredient Identifier: 1C39JW444G

Background: Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formu...

Indication: ⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。

⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。

Associated Conditions: Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer

Associated Therapies: -

Clinical Trials

A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain

Phase 1

Recruiting

Conditions: Metastatic Renal Cell Carcinoma
Brain Metastases

Interventions: Drug: Cabozantinib
Device: Nivolumab
Radiation: Stereotactic Radiosurgery (SRS)

First Posted Date: 2023-11-15

Last Posted Date: 2024-12-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 20

Registration Number: NCT06132945

Locations: 🇺🇸
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumors with HRAS Alterations
Non Small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Pancreatic Ductal Adenocarcinoma (PDAC)
Clear Cell Renal Cell Carcinoma (ccRCC)
Renal Cell Carcinoma (Kidney Cancer)

Interventions: Drug: KO-2806
Drug: Cabozantinib
Drug: Adagrasib

First Posted Date: 2023-09-07

Last Posted Date: 2024-11-28

Lead Sponsor: Kura Oncology, Inc.

Target Recruit Count: 270

Registration Number: NCT06026410

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
🇺🇸
University of Southern California, Los Angeles, California, United States

and more 9 locations

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

Phase 2

Not yet recruiting

Conditions: Lung Cancer
Metastatic NSCLC - Non-Small Cell Lung Cancer
Advanced NSCLC
NSCLC Stage IV

Interventions: Drug: Cabozantinib
Drug: Atezolizumab

First Posted Date: 2023-05-15

Last Posted Date: 2024-05-08

Lead Sponsor: Jun Zhang, MD, PhD

Target Recruit Count: 40

Registration Number: NCT05859217

Locations: 🇺🇸
The University of Kansas Cancer Center - Westwood, Kansas City, Kansas, United States
🇺🇸
The University of Kansas Cancer Center - Indian Creek, Overland Park, Kansas, United States
🇺🇸
The University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States

and more 1 locations

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

Phase 2

Recruiting

Conditions: Locally Advanced Extraskeletal Myxoid Chondrosarcoma
Locally Advanced Leiomyosarcoma
Locally Advanced Liposarcoma
Locally Advanced Undifferentiated Pleomorphic Sarcoma
Locally Advanced Unresectable Soft Tissue Sarcoma
Metastatic Undifferentiated Pleomorphic Sarcoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Cabozantinib
Biological: Ipilimumab
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab

First Posted Date: 2023-05-01

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT05836571

Locations: 🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

and more 21 locations

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Phase 1

Active, not recruiting

Conditions: Advanced Cancer
Clear Cell Renal Cell Carcinoma

Interventions: Drug: 177Lu girentuximab
Drug: Nivolumab
Drug: Cabozantinib
Drug: ArabinoFuranosylGuanine [18F]F-AraG

First Posted Date: 2022-12-23

Last Posted Date: 2024-02-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT05663710

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

Phase 2

Active, not recruiting

Conditions: Differentiated Thyroid Cancer

Interventions: Drug: Cabozantinib

First Posted Date: 2022-12-21

Last Posted Date: 2024-10-03

Lead Sponsor: Grupo Espanol de Tumores Neuroendocrinos

Target Recruit Count: 41

Registration Number: NCT05660954

Locations: 🇪🇸
Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
🇪🇸
Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain
🇪🇸
Complexo Hospitalario Universitario A Coruña, A Coruña, Spain

and more 7 locations

Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1

Recruiting

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Cabozantinib

First Posted Date: 2022-11-14

Last Posted Date: 2024-07-03

Lead Sponsor: University of Utah

Target Recruit Count: 33

Registration Number: NCT05613894

Locations: 🇺🇸
Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumors
Clear Cell Renal Cell Carcinoma

Interventions: Drug: casdatifan
Drug: Cabozantinib

First Posted Date: 2022-09-10

Last Posted Date: 2024-12-04

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 302

Registration Number: NCT05536141

Locations: 🇺🇸
Tisch Cancer Institute, Icahn Mount Sinai Hospital, New York, New York, United States
🇦🇺
Ashford Cancer Centre Research/ICON, Sydney, Australia
🇺🇸
UCLA, Santa Monica, California, United States

and more 21 locations

Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

Phase 2

Recruiting

Conditions: Metastatic Cancer
Castration-resistant Prostate Cancer

Interventions: Drug: Cabozantinib
Drug: Nivolumab

First Posted Date: 2022-08-16

Last Posted Date: 2024-07-18

Lead Sponsor: Rana McKay, MD

Target Recruit Count: 50

Registration Number: NCT05502315

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
University of California San Diego, La Jolla, California, United States

and more 1 locations

Cabozantinib for Patients With Recurrent or Progressive Meningioma

Phase 2

Recruiting

Conditions: Meningioma

Interventions: Drug: Cabozantinib

First Posted Date: 2022-06-21

Last Posted Date: 2024-12-16

Lead Sponsor: Baptist Health South Florida

Target Recruit Count: 24

Registration Number: NCT05425004

Locations: 🇺🇸
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy